Antiplatelet therapy after coronary stenting

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is crucial after percutaneous coronary intervention (PCI) for preventing myocardial infarction, death, and stent thrombosis.
• Current guidelines recommend DAPT for 1 month after bare metal stents (BMS) and 6-12 months after drug-eluting stents (DES), but evidence is conflicting.
• Stent thrombosis rates are declining due to improved techniques and stent design, yet optimal DAPT duration is undetermined.

Purpose of the Study:

• To review the current evidence and ongoing research regarding the optimal duration of DAPT after coronary stent placement.
• To discuss the balance between preventing ischemic events (myocardial infarction, stent thrombosis) and managing bleeding risk associated with DAPT.
• To provide guidance on DAPT duration in the interim period before definitive trial results are available.

Main Methods:

• Review of existing literature, including randomized trials and guideline recommendations.
• Analysis of data concerning the efficacy of DAPT in preventing stent thrombosis and myocardial infarction.
• Evaluation of bleeding risks associated with extended DAPT durations.

Main Results:

• Conflicting data exist regarding the optimal DAPT duration post-PCI.
• Shorter durations (1 month for BMS) are generally accepted, while longer durations (6-12 months for DES) are debated.
• Smaller trials show increased bleeding with longer DAPT, but lack power to assess stent thrombosis or mortality benefits/risks definitively.

Conclusions:

• Optimal DAPT duration after coronary stent placement is not yet established.
• Extended DAPT may benefit high-risk patients but increases bleeding risk.
• Until large trials conclude, continuing DAPT for at least 6-12 months post-PCI is prudent for suitable patients.